Mucosal immunisation: adjuvants and delivery systems.
Mucosal immunisation: adjuvants and delivery systems.
复制标题
DOI：
10.2174/1567201043334588
复制
发表时间：
2004-09
影响因子：
2.4
通讯作者：
P. Moyle;Ross P. McGeary;J. Blanchfield;Istvan Toth
中科院分区：
文献类型：
--
作者：
P. Moyle;Ross P. McGeary;J. Blanchfield;Istvan Toth
由于该技术提供的潜在优势，疫苗的粘膜给药是目前受到高度关注的领域。这些优点包括不需要针头就能接种疫苗，从而提高患者对疫苗接种时间表的依从性，以及诱导免疫应答的能力，这些免疫应答能够预防接种部位的感染。尽管有这些优点，但仍存在许多限制，这些限制目前抑制了我们成功开发新的粘膜疫苗的能力。因此，目前许多研究集中在开发新的佐剂和递送系统以克服这些困难。然而，尽管在这一领域的高度兴趣，相对较少的粘膜疫苗候选人已成功地进展到人类临床试验。在下面的综述中，我们的目的是为读者提供一个关于诱导粘膜免疫反应的免疫系统的概述。此外，审查提供了一个概述了一些微生物（细菌毒素，CpG DNA，细胞因子/趋化因子，活载体和病毒样颗粒）和合成（微球，脂质体和脂肽）的策略，已被调查作为佐剂或粘膜疫苗开发的交付系统，重点是通过口服途径的疫苗交付。
The mucosal administration of vaccines is an area currently receiving a high level of interest due to potential advantages offered by this technique. These advantages include the ability to administer vaccines without need for needles, thus improving patient compliance with vaccination schedules, and the capacity to induce immune responses capable of preventing infections at the site of acquisition. Despite these advantages a number of limitations exist which currently inhibit our ability to successfully develop new mucosal vaccines. As such, much research is currently focused on developing new adjuvants and delivery systems to overcome these difficulties. However, despite high levels of interest in this area, relatively few mucosal vaccine candidates have successfully progressed to human clinical trials. In the review that follows, we aim to provide the reader with an overview of the immune system with respect to induction of mucosal immune responses. Furthermore, the review provides an overview of a number of microbial (bacterial toxins, CpG DNA, cytokines/chemokines, live vectors, and virus like particles) and synthetic (microspheres, liposomes, and lipopeptides) strategies that have been investigated as adjuvants or delivery systems for mucosal vaccine development, with a focus on the delivery of vaccines via the oral route.